RGNX
REGENXBIO Inc.
$6.66
+6.05%
$344.3M
No data for this timeframe.
Vol
Market Cap$344.3M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders50 funds
Inst. Value$201.6M
Inst. Activity8 buys / 5 sells
Insider Activity0B / 2S
Insider Net $-$221.7K
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001590877·Prev Close $6.28
Recent Activity
Jun 5, 2026
short_volume
Short Volume: RGNX — 59.6% short (0.4M / 0.7M)
Short: 388,925 | Exempt: 7,720 | TRF Vol: 652,401 | Short Ratio: 59.6% | Off-exchange volume (dark p
Jun 3, 2026
SEC
REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected three Class II direc
8-K — Impact 3/10
May 29, 2026
Insider
Tasse Daniel was granted 46,600 shares
Director
May 29, 2026
Insider
STUMP DAVID C was granted 46,600 shares
Director
May 29, 2026
Insider
STUMP DAVID C was granted 9,807 shares
Director
May 14, 2026
SEC
REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a year ago, as revenu
8-K — Impact 7/10
Mar 5, 2026
SEC
REGENXBIO reported financial results for Q4 and full year 2025, showing increased revenue driven by collaboration income
8-K — Impact 6/10
Inst.
Hudson Bay Capital Management — ADD
180,000 shares ($1.5M)
Price Targets
$23.82
+257.6% upside
Strong Buy
Current $6.66
Low $10.00
Median $19.00
High $50.00
11 analysts
$10.00
$50.00
Analyst Ratings
6Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 15, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| May 15, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 6, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.12 ▲ +19.4% | $-1.23 — $0.73 | 109% YoY | 7 |
| Next Q | $-1.22 ▼ -9.9% | $-1.63 — $0.32 | -2% YoY | 7 |
| Current FY | $-2.91 ▼ -45.5% | $-4.91 — $1.61 | 23% YoY | 8 |
| Next FY | $-2.74 ▼ -24.7% | $-4.58 — $-0.24 | 6% YoY | 7 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $48.5M | — |
| STATE STREET CORP | $22.9M | — |
| MORGAN STANLEY | $17.3M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.8M | — |
| GOLDMAN SACHS GROUP INC | $15.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Tasse Daniel | A | $0.00 |
| May 29, 2026 | STUMP DAVID | A | $0.00 |
| May 29, 2026 | STUMP DAVID | A | $0.00 |
| May 29, 2026 | Zachary Jennifer | A | $0.00 |
| May 29, 2026 | Zachary Jennifer | A | $0.00 |
50 institutional holders with $201.6M total value (24,009,618 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, MORGAN. Net buying activity: 8 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5,782,808 | $48.5M | 24.0% | — |
| 2 | STATE STREET CORP | 2,731,485 | $22.9M | 11.4% | — |
| 3 | MORGAN STANLEY | 2,066,157 | $17.3M | 8.6% | ADD +71.3% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,007,146 | $16.8M | 8.3% | — |
| 5 | GOLDMAN SACHS GROUP INC | 1,839,463 | $15.4M | 7.6% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,018,901 | $8.5M | 4.2% | — |
| 7 | DIMENSIONAL FUND ADVISORS LP | 1,010,381 | $8.5M | 4.2% | — |
| 8 | Assenagon Asset Management S.A. | 980,611 | $8.2M | 4.1% | ADD +64.5% |
| 9 | Nuveen, LLC | 582,016 | $4.9M | 2.4% | ADD +31.4% |
| 10 | TWO SIGMA INVESTMENTS, LP | 554,892 | $4.6M | 2.3% | TRIM -25.8% |
| 11 | STIFEL FINANCIAL CORP | 392,769 | $3.3M | 1.6% | — |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 390,601 | $3.3M | 1.6% | — |
| 13 | BANK OF AMERICA CORP /DE/ | 324,860 | $2.7M | 1.4% | TRIM -27.6% |
| 14 | VANGUARD FIDUCIARY TRUST CO | 312,064 | $2.6M | 1.3% | — |
| 15 | FMR LLC | 311,268 | $2.6M | 1.3% | ADD +36.3% |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 305,286 | $2.6M | 1.3% | TRIM -57.9% |
| 17 | D. E. Shaw & Co., Inc. | 286,001 | $2.4M | 1.2% | — |
| 18 | AMERIPRISE FINANCIAL INC | 200,352 | $1.7M | 0.8% | TRIM -35.1% |
| 19 | DEUTSCHE BANK AG\ | 196,971 | $1.7M | 0.8% | — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 191,900 | $1.6M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Hudson Bay Capital Management LP | ADD | 140,000 | 180,000 | +28.6% | $1.5M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 33,384 | 139,791 | +318.7% | $1.2M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 55,610 | 115,444 | +107.6% | $967.4K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 9,687 | 113,425 | +1070.9% | $950.5K | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 222,715 | 102,140 | -54.1% | $855.9K | 2026-Q1 |
| HSBC HOLDINGS PLC | ADD | 43,439 | 55,830 | +28.5% | $467.3K | 2026-Q1 |
| Mariner, LLC | TRIM | 55,423 | 37,999 | -31.4% | $318.4K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 37,591 | 22,352 | -40.5% | $187.3K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 34,054 | 13,959 | -59.0% | $117.0K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 2,225 | 6,364 | +186.0% | $53.3K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 804 | 1,678 | +108.7% | $14.1K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 170 | 115 | -32.4% | $964.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 38,995 | 51,129 | +31.1% | $429.00 | 2026-Q1 |
| Assenagon Asset Management S.A. | ADD | 705,403 | 1,160,380 | +64.5% | $16.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 415,306 | 300,609 | -27.6% | $4.3M | 2025-Q4 |
| FMR LLC | ADD | 195,190 | 266,095 | +36.3% | $3.8M | 2025-Q4 |
| Hudson Bay Capital Management LP | TRIM | 200,000 | 140,000 | -30.0% | $2.0M | 2025-Q4 |
| Mariner, LLC | ADD | 32,306 | 55,423 | +71.6% | $797.0K | 2025-Q4 |
| HSBC HOLDINGS PLC | TRIM | 76,331 | 43,439 | -43.1% | $617.7K | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 24,717 | 41,568 | +68.2% | $598.6K | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 19,731 | 37,591 | +90.5% | $541.3K | 2025-Q4 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 92,622 | 34,054 | -63.2% | $436.6K | 2025-Q4 |
| DnB Asset Management AS | ADD | 17,923 | 25,612 | +42.9% | $368.8K | 2025-Q4 |
| FRANKLIN RESOURCES INC | TRIM | 28,871 | 18,970 | -34.3% | $273.2K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 1,953 | 2,460 | +26.0% | $35.4K | 2025-Q4 |
11 unique insiders with 22 transactions. Net insider value: -$221.7K ($0.00 bought, $221.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Tasse Daniel | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | STUMP DAVID C | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | STUMP DAVID C | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | Zachary Jennifer | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | Zachary Jennifer | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | Tasse Daniel | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | Mills Kenneth T. | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | MIGAUSKY GEORGE V | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | KARABELAS ARGERIS N | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | Fox Allan M. | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | Bennett Jean | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | Glucksmann Alexandra | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | Glucksmann Alexandra | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | Mills Kenneth T. | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | MIGAUSKY GEORGE V | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | Fox Allan M. | Director | AWARD | 9,807 | — | — |
| May 29, 2026 | KARABELAS ARGERIS N | Director | AWARD | 46,600 | — | — |
| May 29, 2026 | Bennett Jean | Director | AWARD | 46,600 | — | — |
| May 11, 2026 | PAKOLA STEVE | Chief Medical Officer | SELL | 15,309 | $11.02 | $168.7K |
| Mar 10, 2026 | PAKOLA STEVE | Chief Medical Officer | SELL | 5,124 | $10.35 | $53.0K |
| Feb 1, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | TAX W/H | 4,700 | $11.16 | $52.5K |
| Feb 1, 2026 | PAKOLA STEVE | Chief Medical Officer | TAX W/H | 5,267 | $11.16 | $58.8K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 1 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
3/10
REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected
Jun 3, 2026
MIXED
8-K
7/10
REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a
May 14, 2026
MIXED
8-K
6/10
REGENXBIO reported financial results for Q4 and full year 2025, showing increased revenue driven by
Mar 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (89% buy). Based on 19 analysts: 6 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$23.82 mean target
+257.6% upside
Strong Buy (1.55)
$10.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $6.66 |
| Target Low | $10.00 |
| Target Mean | $23.82 |
| Target Median | $19.00 |
| Target High | $50.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.55) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.12 | $-1.23 | $0.73 | 108.7% | +19.4% | 1↑ 2↓ | $0.1B | 400.5% | 7 |
| Next Q 2026-09-30 |
$-1.22 | $-1.63 | $0.32 | -2.0% | -9.9% | 4↑ 1↓ | $0.0B | 12.5% | 7 |
| Current FY 2026-12-31 |
$-2.91 | $-4.91 | $1.61 | 22.6% | -45.5% | 1↑ 6↓ | $0.2B | 37.5% | 8 |
| Next FY 2027-12-31 |
$-2.74 | $-4.58 | $-0.24 | 5.9% | -24.7% | 1↑ 0↓ | $0.3B | 7.4% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.119 | |
| 7d ago | $0.344 | -0.225 |
| 30d ago | $0.100 | +0.019 |
| 60d ago | $0.100 | +0.019 |
| 90d ago | $0.457 | -0.337 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 15, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| May 15, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 10, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
short_volume
Short Volume: RGNX — 59.6% short (0.4M / 0.7M)
Short: 388,925 | Exempt: 7,720 | TRF Vol: 652,401 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: RGNX — 71.6% short (0.4M / 0.5M)
Short: 358,163 | Exempt: 50 | TRF Vol: 500,166 | Short Ratio: 71.6% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: RGNX — 60.4% short (0.4M / 0.6M)
Short: 386,586 | Exempt: 20 | TRF Vol: 640,486 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: RGNX — 64.4% short (0.4M / 0.7M)
Short: 437,024 | Exempt: 10,392 | TRF Vol: 679,121 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: RGNX — 63.5% short (0.8M / 1.2M)
Short: 750,539 | Exempt: 218 | TRF Vol: 1,182,280 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: RGNX — 64.6% short (1.3M / 2.0M)
Short: 1,271,313 | Exempt: 127,554 | TRF Vol: 1,969,044 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings_calendar
RGNX Q1 2026 Earnings After Market Close — 2026-05-14
May 14, 2026
short_volume
Short Volume: RGNX — 63.6% short (2.6M / 4.1M)
Short: 2,639,126 | Exempt: 212,527 | TRF Vol: 4,148,005 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
RGNX Q1 2026 Earnings After Market Close — 2026-05-06
Mar 5, 2026
earnings_calendar
RGNX Q4 2025 Earnings After Market Close — 2026-03-05
Mar 3, 2026
earnings_calendar
RGNX Q4 2025 Earnings After Market Close — 2026-03-03
Feb 8, 2026
fda_pdufa
PDUFA: RGNX — Clemidsogene lanparvovec in MPS II — 2026-02-08
FDA target action date 2026-02-08 for RGNX (REGENXBIO Inc.). Drug: Clemidsogene lanparvovec. Indication: MPS II. PDUFA target action date for clemidso